PRPH

ProPhase has disintegrated from a $123M-revenue COVID-testing operator (FY2022) into a $4.34M-revenue penny stock, and the decline is structural, not cyclical. Its diagnostics subsidiaries — the entire testing franchise — ceased COVID-19 testing in May 2025 and filed voluntary Chapter 11 petitions on September 22, 2025; the company deconsolidated the Debtors and is now trying to 'restore solvency' primarily by collecting old COVID receivables through court-appointed special counsel. When the plan to fix your balance sheet is to chase down aged receivables from a dead business line, the equity is the residual claimant on a liquidation, not a growing enterprise.

The numbers confirm terminal balance-sheet stress. Cash is $90K against negative operating cash flow of -$8.34M — that is not a runway, it is a fume. Current liabilities of $53.1M dwarf current assets of $3.15M (a ~$50M working-capital hole), stockholders' equity has thinned to $3.51M against $56.4M of liabilities (16.1x leverage), and retained earnings sit at -$73.1M. FY2025 still lost $14.7M with a -415% operating margin. The lone bright spot — gross profit up 1,023% to $1.38M on a 31.9% margin — is meaningless at $4.34M of revenue when D&A alone is $4.83M and R&D was cut 82% to $107K, signaling the pipeline (Equivir, Linebacker, BE-Smart, Nebula genomics) is being starved, not funded. Nebula is up for potential sale.